This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 70.5kDa. The protein migrates as 95-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human EGF R, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human EGF R, His Tag(Cat. No. EGR-H5222) was more than 90% and the molecular weight of this protein is around 90-115 kDa verified by SEC-MALS.
Erbitux (Cetuximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Human EGF R, His Tag (Cat. No. EGR-H5222) captured on CM5 Chip via anti-His antibody can bind Human EGF, Mouse IgG2a Fc Tag (Cat. No. EGF-H525b) with an affinity constant of 2.63 nM as determined in SPR assay (Biacore T200) (Routinely tested).
Loaded Erbitux (Cetuximab) on AHC Biosensor, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.23 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
2e5 of Anti-EGFR CAR-293 cells were stained with 100 μL of 1 μg/mL of Human EGF R, His Tag (Cat. No. EGR-H5222) and negative control protein respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (Routinely tested).
Authors: E Zhukovsky, et al
Journal: US20190153104A1 2019
Authors: W Qiu, et al
Journal: Clin Dev Immunol 2019
Authors: Xinyue Hu, et al.
Journal: Mol Oncol 2018
Application: ELISA & SPR
Authors: Fazekas-Singer J, et al.
Journal: J Allergy Clin Immunol 2018
Application: Western Blot
Authors: Kahl M, et al.
Journal: Protein Expr Purif 2018
Authors: Fazekas-Singer J, et al.
Journal: Oncotarget 2017
Authors: Nath N, et al.
Journal: J Immunol Methods 2017
Authors: Yu X, et al.
Journal: J Immunol Methods 2016
Application: Cell-based assay
Authors: Kant S, et al.
Journal: Mol Microbiol 2015
Application: Assay for Enzyme Activity
Authors: Singer J, et al.
Journal: Mol Cancer Ther 2014
Authors: Olsen DA, et al.
Journal: Clin Chem Lab Med 2013
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.